CoChat

Vascular Normalization as an Emerging Strategy to Enhance Cancer Immunotherapy

Open access
Huang, Yuhui, Goel, Shom, Duda, Dan G., Fukumura, Dai, Jain, Rakesh K. · 2013 · Cancer Research

The DOI matches its Crossref record; 37 of the 38 references it cites were found in a registry or an index.

Abstract

The recent approval of Provenge has brought new hope for anticancer vaccine therapies. However, the immunosuppressive tumor microenvironment seems to impair the efficacy of vaccine therapies. The abnormal tumor vasculature creates a hypoxic microenvironment that polarizes inflammatory cells toward immune suppression. Moreover, tumors systemically alter immune cells' proliferation, differentiation, and function via secretion of growth factors and cytokines. For example, VEGF, a major proangiogenic cytokine induced by hypoxia, plays a critical role in immunosuppression via these mechanisms. Hence, antiangiogenic treatment may be an effective modality to potentiate immunotherapy. Here, we discuss the local and systemic effects of VEGF on tumor immunity and propose a potentially translatable strategy to re-engineer the tumor–immune microenvironment and improve cancer immunotherapy by using lower “vascular normalizing” doses of antiangiogenic agents. Cancer Res; 73(10); 2943–8. ©2013 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/0008-5472.can-12-4354

Cites

37 of 37 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 37 references

Cited by

See all 686

Metadata

Authors
Huang, Y., Goel, S., Duda, D. G., Fukumura, D., & Jain, R. K.
Affiliations
Harvard University (US)
Corresponding author
Jain, Rakesh K.
Venue
Cancer Research
Published
2013-05-12
Volume
73
Issue
10
Pages
2943-2948
ISSN
  • 0008-5472 (ISSN-L)
  • 1538-7445
OpenAlex
W2131783235
Cited by
669
References
38
Citations by year
2026: 35 · 2025: 43 · 2024: 42 · 2023: 69 · 2022: 66 · 2021: 75 · 2020: 61 · 2019: 48 · 2018: 56 · 2017: 45 · 2016: 41 · 2015: 47 · 2014: 25 · 2013: 16
FWCI
4.05
Type
journal article
Language
en
Open access
Locations
  • Cancer Research (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • National Cancer Institute (R01CA115767, R01CA159258, R01CA085140, R01CA096915, P01CA080124, R01CA126642, R01CA163815, R21CA139168)
  • National Institute of Biomedical Imaging and Bioengineering (P41EB015903)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Keywords
vascular normalization, cancer immunotherapy, tumor microenvironment, anti-angiogenic therapy, vascular endothelial growth factor, tumor hypoxia, immunosuppression, tumor vasculature, antitumor immunity, sipuleucel-T, cancer vaccines
MeSH terms
Animals, Humans, Immune Tolerance, Immunotherapy, Neoplasms, T-Lymphocytes, Angiogenesis Inhibitors, Vascular Endothelial Growth Factor A, Tumor Microenvironment

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Vascular Normalization as an Emerging Strategy to Enhance Cancer Immunotherapy. https://app.cochat.ai/papers/10.1158/0008-5472.can-12-4354
The paper
Huang, Y., Goel, S., Duda, D. G., Fukumura, D., & Jain, R. K. (2013). Vascular Normalization as an Emerging Strategy to Enhance Cancer Immunotherapy. Cancer Research. https://doi.org/10.1158/0008-5472.can-12-4354

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.